68 related articles for article (PubMed ID: 17164689)
1. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
Molden E; Lunde H; Lunder N; Refsum H
Ther Drug Monit; 2006 Dec; 28(6):744-9. PubMed ID: 17164689
[TBL] [Abstract][Full Text] [Related]
2. CYP1A2*F Polymorphism contributes at least partially to the Variability of Plasma Levels of Dehydroaripiprazole, an active Metabolite of Aripiprazole, in Schizophrenic Patients.
Suzuki T; Nagai G; Mihara K; Tomori Y; Kagawa S; Nakamura A; Nemoto K; Kondo T
Drug Metab Bioanal Lett; 2023 Oct; ():. PubMed ID: 37855290
[TBL] [Abstract][Full Text] [Related]
3. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling.
Bandín-Vilar E; Toja-Camba FJ; Vidal-Millares M; Durán-Maseda MJ; Pou-Álvarez M; Castro-Balado A; Maroñas O; Gil-Rodríguez A; Carracedo Á; Zarra-Ferro I; Soy D; Fernández-Ferreiro A; Mangas-Sanjuan V; Mondelo-García C
Psychiatry Res; 2024 Mar; 333():115721. PubMed ID: 38245977
[TBL] [Abstract][Full Text] [Related]
4. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports.
McGrane IR; Lindbloom TJ; Munjal RC
Ment Health Clin; 2021 Sep; 11(5):297-300. PubMed ID: 34621606
[TBL] [Abstract][Full Text] [Related]
5. Towards Precision Medicine in Clinical Practice: Alinity C vs. UHPLC-MS/MS in Plasma Aripiprazole Determination.
Toja-Camba FJ; Bandín-Vilar E; Hermelo-Vidal G; Feitosa-Medeiros C; Cañizo-Outeiriño A; Castro-Balado A; Varela-Rey I; Zarra-Ferro I; Fernández-Ferreiro A; Mondelo-García C
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258114
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions.
Urichuk L; Prior TI; Dursun S; Baker G
Curr Drug Metab; 2008 Jun; 9(5):410-8. PubMed ID: 18537577
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.
Kubo M; Koue T; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2007 Oct; 22(5):358-66. PubMed ID: 17965519
[TBL] [Abstract][Full Text] [Related]
9. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
10. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.
Kirschbaum KM; Müller MJ; Malevani J; Mobascher A; Burchardt C; Piel M; Hiemke C
World J Biol Psychiatry; 2008; 9(3):212-8. PubMed ID: 17853280
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.
Lin SK; Chen CK; Liu YL
J Clin Psychopharmacol; 2011 Dec; 31(6):758-62. PubMed ID: 22020350
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of aripiprazole in healthy Korean subjects.
Jeon JY; Chae SW; Kim MG
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):293-304. PubMed ID: 26902506
[TBL] [Abstract][Full Text] [Related]
15. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Cabaleiro T; Talegón M; Sánchez-Rojas SD; Abad-Santos F
J Clin Psychopharmacol; 2016 Dec; 36(6):608-614. PubMed ID: 27684290
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs.
Ragia G; Dahl ML; Manolopoulos VG
Curr Drug Metab; 2016; 17(3):227-36. PubMed ID: 26651976
[TBL] [Abstract][Full Text] [Related]
18. Quantitative levels of aripiprazole parent drug and metabolites in urine.
McEvoy J; Millet RA; Dretchen K; Morris AA; Corwin MJ; Buckley P
Psychopharmacology (Berl); 2014 Dec; 231(23):4421-8. PubMed ID: 25345737
[TBL] [Abstract][Full Text] [Related]
19. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia.
Boulton DW; Kollia G; Mallikaarjun S; Komoroski B; Sharma A; Kovalick LJ; Reeves RA
Clin Pharmacokinet; 2008; 47(7):475-85. PubMed ID: 18563956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
